

November 14, 2013

The Manager
Listing Department
The National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G. Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

Script Code : lykalabs

Sub : Un-audited Standalone and Consolidated Financial Results (Provisional) for the Quarter ended September 30, 2013.

We forward herewith copy of the Un-audited Standalone and Consolidated Financial Results of the Company separately for the quarter ended September 30, 2013 which were taken on record by the Board of Directors at its meeting held today together with Limited Review Report by Auditors thereon for your information and record.

Thanking you,

Yours faithfully,
For LYKA LABS LIMITED


P. G. HINDIA
COMPANY SECRETARY

Lyka Labs Limited



Healthcare through Innovation

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30TH SEPTEMBER, 2013

Particular	Quarter Ended	Previous Quarter Ended	Corresponding 3 Month ended in the Previous period ended	Year to date figure for Current period Ended	Year to date figure for previous period Ended	Year to date figure for Previous year Ended
	30-Sep-2013 (Unaudited)	30-Jun-2013 (Unaudited)	30-Sep-2012 (Unaudited)	30-Sep-2013 (Unaudited)	30-Sep-2012 (Unaudited)	31-Mar-2013 (Audited)
1 Income from operations						
(a) Net Sales/Income from operations (Net of excise duty)	1665.67	1558.28	2292.05	3223.95	4271.85	8714.95
(b) Other Operating Income	113.33	148.38	104.35	259.71	246.51	757.76
Total income from operations (net)	1,779.00	1,704.66	2,396.40	3,483.66	4,518.36	9,472.71
2 Expenses						
(a) Cost of Materials Consumed	822.47	907.84	1115.66	1,730.31	2,043.55	4,621.22
(b) Purchase of traded goods	70.31	69.65	375.64	139.96	601.82	1056.81
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	107.03	-21.50	111.60	65.53	171.43	-11.08
(d) Employee benefits expense	295.03	290.42	252.95	585.45	518.10	1174.41
(e) Depreciation and amortisation expense	104.44	104.29	82.00	208.73	160.01	329.90
(f) Other expenses	379.97	380.71	336.38	760.68	701.84	1466.72
Total expenses	1779.25	1731.41	2274.23	3510.66	4196.56	8637.98
3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)	-0.25	-26.75	122.17	-27.00	321.81	834.73
4 Other Income	83.66	97.55	117.17	181.21	167.58	372.35
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	83.41	70.80	239.34	154.21	489.39	1207.08
6 Finance costs	412.03	397.56	372.11	809.59	740.44	1511.92
7 Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5+6)	-328.62	-326.75	-132.77	-655.38	-251.05	-304.84
8 Exceptional Items (Net)						
a Amortization of Expenses for restructuring			-12.48		-24.97	-37.46
b Reversal of Sicom Excess provision/Profit on sale of Fixed Assets					62.21	62.21
c Fixed Assets written off	-24.90			-24.90		
Total Exceptional Items (Net)	-24.90		-12.48	-24.90	37.24	24.76
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	-353.52	-326.75	-145.25	-680.28	-213.81	-280.08
10 Tax Expenses			-0.39		-0.39	0.00
11 Net Profit/(Loss) from Ordinary activities after tax (9+10)	-353.52	-326.75	-145.64	-680.28	-214.20	-280.09
12 Extraordinary Item (net of tax expenses)						
13 Net Profit/(Loss) for the period (11+12)	-353.52	-326.75	-145.64	-680.28	-214.20	-280.09
14 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00
15 Reserve, excluding Revaluation Reserve as per balance sheet of previous accounting year						
16 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))						4365.59
(a) Basic	-1.64	-1.51	-0.67	-3.15	-0.99	-1.30
(b) Diluted	-1.64	-1.51	-0.67	-3.15	-0.99	-1.30
16 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))						
(a) Basic	-1.64	-1.51	-0.67	-3.15	-0.99	-1.30
(b) Diluted	-1.64	-1.51	-0.67	-3.15	-0.99	-1.30

Lyka Labs Limited



Healthcare through innovation

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30TH SEPTEMBER, 2013

Particular	Quarter Ended	Previous Quarter Ended	Corresponding 3 Month ended in the Previous period ended	Year to date figure for Current period Ended	Year to date figure for previous period Ended	(Rs in Lakhs)
						Year to date figure for Previous year Ended
	30-Sep-2013 (Unaudited)	30-Jun-2013 (Unaudited)	30-Sep-2012 (Unaudited)	30-Sep-2013 (Unaudited)	30-Sep-2012 (Unaudited)	31-Mar-2013 (Audited)
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
Number of shares	16552735	16552735	16552735	16552735	16552735	16552735
percentage of shareholding	76.70	76.70	76.70	76.70	76.70	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4142715	4108115	4965615	4665615	4965615	4685815
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.41	81.72	98.77	92.81	98.77	92.806
- Percentage of shares (as a % of the total share capital of the company)	19.20	19.04	23.01	21.62	23.01	21.62
b. Non - encumbered						
- Number of shares	884550	919150	61650	361650	61650	361650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.59	18.283	1.23	7.19	1.23	7.19
- Percentage of shares (as a % of the total share capital of the company)	4.09	4.26	0.29	1.68	0.29	1.68


PARTICULARS			
INVESTOR COMPLAINTS		3 Month Ended	
		30-Sep-13	
Pending at the beginning of the quarter			
Received during the quarter		1	
Disposed of during the quarter		1	
Remaining unresolved at the end of the quarter			

Lyka Labs Limited

Healthcare through Innovation

Standalone statement of Assets and Liabilities**(Rs.in lakhs)**

Particulars		As at Current year ended 30th Sept, 2013	As at Previous year ended 31st March, 2013
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,266.57	2,266.57
	(b) Reserves and Surplus	3,829.24	4,540.45
	Sub-Total -Shareholders' Fund	6,095.81	6,807.02
2	Non-Current Liabilities		
	(a) Long-Term Borrowings	7,200.19	6,178.10
	(b) Other Long-Term Liabilities	88.52	85.20
	(c) Long-Term Provisions	357.91	313.32
	Sub -Total -Non -Current liabilities	7,646.62	6,576.62
3	Current Liabilities		
	(a) Short-Term Borrowings	3,768.83	4,483.13
	(b) Trade Payables	2,722.50	3,769.76
	(c) Other Current Liabilities	3,838.72	3,039.64
	(d) Short-Term Provisions	48.75	67.22
	Sub -Total -Current liabilities	10,378.80	11,359.75
	TOTAL-EQUITY AND LIABILITIES	24,121.23	24,743.39
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	9,136.32	9,256.47
	(ii) Capital Work-in-Progress	866.51	684.56
	(iii) Intangible Assets	275.32	289.27
	(iii) Intangible assets under development	1,031.03	853.22
		11,309.18	11,083.52
	(b) Non-Current Investments	2,021.63	2,021.62
	(c) Long-Term Loans and Advances	1,554.95	1,534.95
	Sub -Total -Non-Current assets	14,885.76	14,640.09
2	Current Assets		
	(a) Inventories	1,127.38	1,455.55
	(b) Trade Receivables	5,597.87	5,932.21
	(c) Cash and Cash Equivalents	261.66	456.18
	(d) Short-Term Loans and Advances	2,109.52	2,120.32
	(e) Other Current Assets	139.04	139.04
	Sub -Total -Current assets	9,235.47	10,103.30
	TOTAL-ASSETS	24,121.23	24,743.39

**FOR LYKA LABS LIMITED**


(N.I. Gandhi)
(Chairman & Managing Director)



Contd...3/-..

Notes:

1. The above results were duly considered by the Audit Committee on 14th November, 2013, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 14th November, 2013.
2. During the Quarter the Company has charged to Profit & Loss Account Rs.18.91 lacs being depreciation on revalued assets.
3. On 31st October, 2013 a fire took place in one of our plant at Ankleshwar factory which resulted in damage of certain Fixed Assets and materials in process. Management is in the process of assessing the damage to lodge a claim for the same with the insurance company.
4. During the Quarter, the Company has capitalised interest of Rs.7.14 lacs towards the Term Loan for Ankleshwar Expansion and Rs.28.35 lacs towards pending allocation to Intangible Assets.
5. The Company has one Single Segment "Pharmaceuticals".
6. Previous periods figures have been regrouped/rearranged wherever necessary.



For LYKA LABS LIMITED

(N. I. GANDHI)
Chairman & Managing DirectorMumbai
14-Nov-13

Lyka Labs Limited



Healthcare through Innovation

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2013

(Rs. in Lakhs)

Particulars	Quarter Ended 30-Sep-2013	Previous Quarter Ended June-2013	Corresponding 3 Month ended in the Previous period ended 30-Sep-2012	Year To Date Figures For Current period ended 30-Sep-2013	Year To Date Figures For Previous period ended 30-Sep-2012	Previous Year ended 31-March-2013
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from operations						
(a) Net Sales/Income from operations (Net of excise duty)	2,410.29	2,312.65	3,278.77	4,722.94	6,291.48	12,035.13
(b) Other Operating Income	161.79	187.70	129.32	349.49	292.46	876.96
Total Income from operations (net)	2,572.08	2,500.35	3,408.09	5,072.43	6,583.94	12,712.09
2 Expenses						
(a) Cost of Materials Consumed	822.47	907.84	1,115.66	1,730.31	2,043.55	4,646.38
(b) Purchase of traded goods	256.95	142.74	696.49	399.69	1,355.75	2,296.01
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade.	199.16	76.97	82.71	276.13	111.78	-251.89
(d) Employee benefits expense	342.72	337.57	298.94	680.29	597.77	1,379.62
(e) Depreciation and amortisation expense	181.65	179.90	127.84	361.58	251.18	1,169.58
(f) Other expenses	584.08	670.15	571.13	1,254.23	1,150.68	2,852.14
Total expenses	2,387.03	2,315.17	2,892.67	4,702.20	5,510.71	11,891.84
3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)	185.05	185.18	515.52	370.23	1073.23	820.25
4 Other Income	88.26	103.47	119.20	192.73	182.02	334.74
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	274.31	288.65	634.81	562.96	1,255.25	1,154.99
6 Finance costs	524.74	492.58	481.45	1,017.32	968.54	1,911.32
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	-250.43	-203.93	153.36	-454.36	286.71	-756.33
8 (i) Exceptional Items (Net)						
a Profit On Sale Of Fixed Assets	-	-	-	-	-	772.43
b Foreign Currency Monetary Item Translation	-	-	-	-	-	-
c Amortization of Expenses for restructuring	-	-	-12.48	-	-24.97	-37.46
d Fixed Assets Written Off	-24.90	-	-	-24.90	62.21	62.21
Total Exceptional items(Net)	-24.90	-	-12.48	-24.90	37.24	797.18
(ii) Provision for Taxation of earlier years	-	-	-0.39	-	-0.39	-
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	-275.33	-203.93	140.49	-479.26	323.56	40.84
10 Tax Expenses	-	-	-	-	-	-
11 Net Profit/(Loss) from Ordinary activities after tax (9+10)	-275.33	-203.93	140.49	-479.26	323.56	40.84
12 Extraordinary Item (net of tax expenses)	-	-	-	-	-	-
13 Net Profit/(Loss) for the period (11+12)	-275.33	-203.93	140.49	-479.26	323.56	40.84
14 Share of Profit/(Loss) of associates	-	-	-	-	-	-
15 Minority Interest	27.20	42.71	99.04	69.91	187.04	111.62
16 Net Profit/(Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	-302.63	-248.64	41.45	-549.17	136.52	-70.78
17 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00

Lyka Labs Limited



Healthcare through Innovation

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2013

(Rs. in Lakhs)

Particulars	Quarter Ended 30-Sep-2013 (Unaudited)	Previous Quarter Ended 30-June-2013 (Unaudited)	Corresponding 3 Month ended In the Previous period ended 30-Sep-2012 (Unaudited)	Year To Date Figures For Current period ended 30-Sep-2013 (Unaudited)	Year To Date Figures For Previous period ended 30-Sept-2012 (Unaudited)	Previous Year ended 31-March-2013 (Audited)
18 Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year	-	-	-	-	-	3,423.79
19 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))						
(a) Basic	-1.40	-1.14	0.19	-2.54	0.63	-0.33
(b) Diluted	-1.40	-1.14	0.19	-2.54	0.63	-0.33
19 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))						
(a) Basic	-1.40	-1.14	0.19	-2.54	0.63	-0.33
(b) Diluted	-1.40	-1.14	0.19	-2.54	0.63	-0.33
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding:						
- Number of shares	16552735	16552735	16552735	16552735	16552735	16552735
- Percentage of shareholding	76.70	76.70	76.70	76.70	76.70	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4142715	4108115	4965615	4665615	4965615	4665615
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.41	81.72	90.77	82.81	98.77	92.81
- Percentage of shares (as a % of the total share capital of the company)	19.20	19.04	23.01	21.62	23.01	21.62
b. Non - encumbered						
- Number of shares	884550	919150	61650	361650	61650	361650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.59	18.28	1.23	7.19	1.23	7.19
- Percentage of shares (as a % of the total share capital of the company)	4.09	4.26	0.29	1.68	0.29	1.68

B

PARTICULARS	3 Month ended 30th sept 2013
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	-